Pathologic neovascular endothelium

Pathologic neovascular endothelium refers to the specialized, rapidly proliferating endothelial cells that form new, disorganized, and hyperpermeable blood vessels in response to disease-driven angiogenic stimuli. Unlike the quiescent endothelium of healthy adult vasculature, these cells express distinct molecular markers such as vascular endothelial growth factor receptors (VEGFRs), integrin alpha-v beta-3, and endoglin (CD105) (PMID: 15549031). This cellular target is critical in the progression of solid tumors, where it facilitates nutrient delivery and metabolic waste removal, and in exudative ocular diseases like wet age-related macular degeneration, where it causes fluid leakage and hemorrhage (NIH, StatPearls). Therapeutic strategies targeting this endothelium include anti-angiogenic agents that block growth factor signaling and vascular disrupting agents (VDAs) that induce the rapid collapse of the existing pathologic vessel cytoskeleton (PMID: 15155305). Because these vessels are structurally fragile and functionally distinct from healthy vasculature, they provide a unique opportunity for selective therapeutic intervention, although systemic inhibition can lead to side effects such as hypertension and impaired wound healing.

Other names

Tumor neovasculatureAngiogenic endotheliumDiseased vasculatureNeovascular tuftsPathologic angiogenesis

Inhibition of pro-angiogenic growth factor signaling (e.g., VEGF/VEGFR), competitive antagonism of adhesion receptors (e.g., integrins), and microtubule destabilization leading to vascular collapse.